Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-5960
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis ; volume:10 ; number:1 ; day:4 ; month:7 ; year:2022 ; pages:1-17 ; date:12.2022
Acta Neuropathologica Communications ; 10, Heft 1 (4.7.2022), 1-17, 12.2022
- Urheber
-
Jiang, Richeng
Smailovic, Una
Haytural, Hazal
Tijms, Betty M.
Li, Hao
Haret, Robert Mihai
Shevchenko, Ganna
Chen, Gefei
Abelein, Axel
Gobom, Johan
Frykman, Susanne
Sekiguchi, Misaki
Fujioka, Ryo
Watamura, Naoto
Sasaguri, Hiroki
Nyström, Sofie
Hammarström, Per
Saido, Takaomi C.
Jelic, Vesna
Syvänen, Stina
Zetterberg, Henrik
Winblad, Bengt
Bergquist, Jonas
Visser, Pieter Jelle
Nilsson, Per
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40478-022-01398-5
- URN
-
urn:nbn:de:101:1-2022082321475343171044
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jiang, Richeng
- Smailovic, Una
- Haytural, Hazal
- Tijms, Betty M.
- Li, Hao
- Haret, Robert Mihai
- Shevchenko, Ganna
- Chen, Gefei
- Abelein, Axel
- Gobom, Johan
- Frykman, Susanne
- Sekiguchi, Misaki
- Fujioka, Ryo
- Watamura, Naoto
- Sasaguri, Hiroki
- Nyström, Sofie
- Hammarström, Per
- Saido, Takaomi C.
- Jelic, Vesna
- Syvänen, Stina
- Zetterberg, Henrik
- Winblad, Bengt
- Bergquist, Jonas
- Visser, Pieter Jelle
- Nilsson, Per
- SpringerLink (Online service)
Ähnliche Objekte (12)
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Blood-based molecular biomarkers for Alzheimer’s disease
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease